
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: [year=2010; month=7; day=22; hr=12; min=27; sec=7; ms=787;]

Validated By CRFValidator v 1.0.3

Application No: 10580601 Version No: 2.0

Input Set:

Output Set:

Started: 2010-07-16 14:43:32.916

Finished: 2010-07-16 14:43:34.889

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 973 ms

Total Warnings: 6

Total Errors: 0

No. of SeqIDs Defined: 8

Actual SeqID Count: 8

Error code		Error Description									
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(1)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(2)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(3)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(4)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(5)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(8)

SEQUENCE LISTING

<110>	AUSTEN, MATTHIAS BURK, ULRIKE	
<120>	METHOD FOR PREVENTING AND TREATING DIABETES USING NEURTURIN	
<130>	WEICKM-0058	
<140>	10580601	
<141>	2010-07-16	
	PCT/EP04/13534	
<151>	2004-11-29	
<150>	EP 03027383.3	
<151>	2003-11-27	
<160>	8	
<170>	Detenting venerical 2 5	
1/0>	PatentIn version 3.5	
<210>	1	
<211>	21	
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: Synthetic	
	mDG770 transgene specific forward primer	
<400>	1	
gctat	cetgt etggatgtge e	21
<210>	2	
<211>	21	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: Synthetic	
	mDG770 transgene specific reverse primer	
<400>	2	
aaggad	cacct cgtcctcata g	21
<210>		
<211>		
<212>		
.∠⊥ 3>	Artificial Sequence	
<220>		
<223>	Description of Artificial Sequence: Synthetic	
	mDG770-1 forward primer	

<400> 3 gcctatgagg acgaggtgtc c		21
<210> 4 <211> 19 <212> DNA <213> Artificial Sequence		
<220> <223> Description of Artificial Sequence: Synthetic mDG770 reverse primer		
<400> 4 agctcttgca gcgtgtggt		19
<210> 5 <211> 20 <212> DNA <213> Artificial Sequence		
<220> <223> Description of Artificial Sequence: Synthetic mDG770 probe		
<400> 5 tectggaegt geacageege		20
<210> 6 <211> 594 <212> DNA <213> Homo sapiens		
<400> 6 atgcagcgct ggaaggcggc ggccttggcc tcagtgctct gcagctccgt	gctgtccatc	60
tggatgtgtc gagagggcct gcttctcagc caccgcctcg gacctgcgct	ggtccccctg	120
caccgcctgc ctcgaaccct ggacgcccgg attgcccgcc tggcccagta	ccgtgcactc	180
ctgcaggggg ccccggatgc gatggagctg cgcgagctga cgccctgggc	tgggcggccc	240
ccaggtccgc gccgtcgggc ggggccccgg cggcggcgcg cgcgtgcgcg	gttgggggcg	300
cggccttgcg ggctgcgcga gctggaggtg cgcgtgagcg agctgggcct	gggctacgcg	360
teegaegaga eggtgetgtt eegetaetge geaggegeet gegaggetge	egegegegte	420
tacgaceteg ggetgegaeg actgegeeag eggeggegee tgeggeggga	gegggtgege	480
gcgcagccct gctgccgccc gacggcctac gaggacgagg tgtccttcct	ggacgcgcac	540
agccgctacc acacggtgca cgagctgtcg gcgcgcgagt gcgcctgcgt	gtga	594

<210> 7

<211> 197

<212> PRT

<213> Homo sapiens

<400> 7

Met Gln Arg Trp Lys Ala Ala Ala Leu Ala Ser Val Leu Cys Ser Ser 1 5 10 15

Val Leu Ser Ile Trp Met Cys Arg Glu Gly Leu Leu Leu Ser His Arg 20 25 30

Leu Gly Pro Ala Leu Val Pro Leu His Arg Leu Pro Arg Thr Leu Asp 35 40 45

Ala Arg Ile Ala Arg Leu Ala Gl
n Tyr Arg Ala Leu Leu Gl
n Gly Ala 50 $$ 55 $$ 60

Pro Asp Ala Met Glu Leu Arg Glu Leu Thr Pro Trp Ala Gly Arg Pro 65 70 75 80

Pro Gly Pro Arg Arg Arg Ala Gly Pro Arg Arg Arg Ala Arg Ala
85 90 95

Arg Leu Gly Ala Arg Pro Cys Gly Leu Arg Glu Leu Glu Val Arg Val 100 105 110

Ser Glu Leu Gly Leu Gly Tyr Ala Ser Asp Glu Thr Val Leu Phe Arg 115 120 125

Tyr Cys Ala Gly Ala Cys Glu Ala Ala Ala Arg Val Tyr Asp Leu Gly 130 135 140

Ala Gl
n Pro Cys Cys Arg Pro Thr Ala Tyr Glu Asp Glu Val Ser Phe
 $165 \hspace{1.5cm} 170 \hspace{1.5cm} 175$

Leu Asp Ala His Ser Arg Tyr His Thr Val His Glu Leu Ser Ala Arg 180 185 190

Glu Cys Ala Cys Val

```
<210> 8
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 8
```

tttttttt ttttt

16